Array
(
[1552973973] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1552974481] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1552985371] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1552986024] => Array
(
[publish_future_post] => Array
(
[ab4cde51466f45dd3dfb269808f7d352] => Array
(
[schedule] =>
[args] => Array
(
[0] => 428938
)
)
)
)
[1552990511] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1552990552] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1552995209] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553002326] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1553003074] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553008673] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1553011624] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553014611] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553526000] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1553554832] => Array
(
[publish_future_post] => Array
(
[aa11aa901e9c7fa426bc76aa2905e5a4] => Array
(
[schedule] =>
[args] => Array
(
[0] => 427034
)
)
)
)
[1553641250] => Array
(
[publish_future_post] => Array
(
[1f3d24059f96d9e259518bca8d2c4d45] => Array
(
[schedule] =>
[args] => Array
(
[0] => 399265
)
)
)
)
[1553641252] => Array
(
[publish_future_post] => Array
(
[f424dbe879bbeb64820a496b9b964c34] => Array
(
[schedule] =>
[args] => Array
(
[0] => 425172
)
)
)
)
[1554069658] => Array
(
[publish_future_post] => Array
(
[30870f619857112e7f5a94a898b1f874] => Array
(
[schedule] =>
[args] => Array
(
[0] => 428209
)
)
)
)
[1554674448] => Array
(
[publish_future_post] => Array
(
[ff60c73b1e4862a319c959dd8a390668] => Array
(
[schedule] =>
[args] => Array
(
[0] => 426546
)
)
)
)
[1560808829] => Array
(
[publish_future_post] => Array
(
[b5d3dc26a5d6e8c9ef68ff7210d9c108] => Array
(
[schedule] =>
[args] => Array
(
[0] => 413991
)
)
)
)
[1572217239] => Array
(
[publish_future_post] => Array
(
[e2d49b23925e3371aea8db1c72521461] => Array
(
[schedule] =>
[args] => Array
(
[0] => 421241
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
)
Etiquetas: 14 mayo 2007, 14/05/2007, 14/05/2008, 2005/2006, Abatacept, Agencia Europea de Medicamentos, Antibacterianos, Antidiabéticos, Antidiabéticos orales, Antitrombóticos, Autorizaciones de medicamentos, Citostáticos, Colesevelam, Darunavir, Decitabina, Deferasirox, EMEA, Entecavir, Estiripentol, Eszopiclona, Exenatida, Fanolesomab 99 Tc, FDA, Fluoroquinolonas, Food Drug Administration, Gemtuzumab ozogamicina, Grupo, Hormonas hipotalámicas e hipofisarias, Hormonas liberadores de gonadotropinas, Inmunoestimulantes, Inmunosupresores selectivos, Ivermectina, Laboratorio, Laxantes, Lenalidomida, Lubiprostona, Madrid, Medicamento, medicamentos, Micafungina, Natalizumab, Nepafenaco, Nuevos principios activos, PaM digital, Panitumumab, Panorama Actual del Medicamento, Parches de testosterona, Perflutren, Porfímero, Pramlintida, Principio activo, Rimonabant, Rufinamida, salud, Sanidad, Secretina, Sitaxentán, Telbivudina, Temoporfina, Terapia cardiaca, Ziconotida, Zileuton.
Etiquetas: 2007, Abatacept, Actividad, Atomoxetina, Eculizumab, Efecto, EMEA, Enero 2008, Epoetina Delta, Grupo A.T.C, Iobenguano, Ivabrandina, Lenalidomida, Madrid, Maraviroc, Mecasermina, Medicamentos huérfanos, Nelarabina, Nuevos, Papiloma humano virus, Perflutren, Presentación, principios activos, Ranibizumad, Retapamulina, Revisión, salud, Sanidad, Sistema Nacional de Salud, Sitagliptina, Tabla, Trabectedina, Volumen 32, Ziconotida.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)